Sunpharma vs Cipla Q3 FY25

Sun Pharma delivered a solid Q3 FY25 with consolidated sales of INR 13,437 crore, up 10.5% YoY, driven by strong India (13.8% growth) and emerging markets (10.1% growth). EBITDA margin expanded 120 bps YoY to 29.3%, aided by lower material costs and milestone income. Adjusted PAT grew 24.1% YoY to INR 3,220 crore. Specialty sales rose 24.8% to $370M, with balanced contribution from US and ex-US markets. India business gained 40 bps market share to 8.2%, led by volume and new launches. R&D spend was lower than guided at 6.3% of sales due to clinical trial delays; FY25 R&D guidance trimmed to <7%. Management remains focused on specialty pipeline, including Leqselvi (litigation oral arguments in April) and Antibe acquisition. Key risk: potential US tariff policy changes and FDA compliance issues at Halol facility could impact generics recovery.

Guidance read

FY25 R&D spend to be less than 7% of sales: Due to delays in clinical trial initiation, R&D expenditure for FY25 is expected to be below the earlier guidance of 7% of sales. Leqselvi launch timeline dependent on litigation outcome: Oral arguments for Leqselvi patent litigation expected in April 2025; if favorable, launch could occur before patent expiry in December 2026. Specialty sales growth to normalize after Q3 inventory build: Q3 specialty sales benefited from inventory build at a partner; next quarter sales are expected to be lower excluding milestones.

Risk read

Key risks include US Tariff and Policy Uncertainty — Potential US tariff changes and new administration policies could impact Sun Pharma's US generics and specialty business.; FDA Compliance at Halol Facility — Halol facility remains under FDA scrutiny; reinspection has been invited but not scheduled, delaying new product approvals.; Leqselvi Litigation Risk — If the patent litigation outcome is unfavorable, Leqselvi launch could be delayed until December 2026, impacting specialty growth.; Clinical Trial Delays Impacting R&D Pipeline — Delays in finalizing protocols and starting clinical trials have led to lower R&D spend and may push back pipeline milestones..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.

Cipla reported Q3 FY25 revenue of INR 7,073 crore (+8% YoY) and EBITDA margin of 28% (+184bps YoY), driven by strong India (10% growth), South Africa (21% ZAR), and EMEU (20% USD) performance. US revenue was $226M, impacted by lanreotide supply disruption, but Albuterol market share reached 21%. Management reiterated FY26 top-line growth guidance and expects EBITDA for FY25 to exceed the 24.5%-25.5% range. Key catalysts include generic Advair launch in H1 FY26 and Abraxane in H2 FY26 from the now-cleared Goa facility. Risks include regulatory delays at Bengaluru and MDI facilities, and potential US tariff impacts, though US manufacturing de-risks some exposure.

Guidance read

FY26 top-line growth guidance retained: Management reiterated guidance to grow top line in FY26, with further profitability guidance to be provided after budget finalization. Generic Advair launch in late H1 FY26: Cipla plans to launch generic Advair from its US facility in late first half of FY26, with de-risking progressing as expected. Abraxane launch in H2 FY26: Abraxane launch expected from Goa facility post-approval, likely in back end of second half FY26 (Q4 FY26). FY25 EBITDA margin to exceed guidance: EBITDA for FY25 is trending higher than earlier guidance of 24.5%-25.5%, with Q3 margin at 28% but not sustainable.

Risk read

Key risks include Regulatory delays at Bengaluru and MDI facilities — US FDA issued Form 483 observations at Virgonagar (Bengaluru) and MDI facilities; official classification awaited, potentially delaying product approvals.; Lanreotide supply disruption recovery timeline — Lanreotide supply issues impacted US revenue; management expects normalization by end of Q4, but full capacity recovery may extend into Q1 FY26.; US tariff policy uncertainty — Potential US tariffs on pharmaceutical imports could impact margins; management noted de-risking via US facilities but awaits policy clarity.; Generic Revlimid revenue decline — Revlimid revenue is flat sequentially and expected to decline as competition increases; new launches may only partially offset the reduction..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.